Skip to main content
JBIOJade Biosciences, Inc.Sell4.9·$16.65-4.20%

Jade Biosciences (JBIO) Q2 2026 earnings — TrendMatrix coverage

MISS · WIDER LOSS-40.3% vs estimateEPS -$0.76 vs -$0.54 estCurrent verdict Sell 4.9/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
-$0.76
Estimate
-$0.54
Surprise
-40.3%
Score today
4.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

Jade Biosciences (JBIO) reported a wider loss than forecast — diluted EPS of -$0.76 against the -$0.54 estimate (a 40.3% shortfall).

Current read · as of 2026-09-17

Where TrendMatrix's rating stands now

TrendMatrix currently rates JBIO Sell at 4.9/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -40.3% surprise compares with a -27.6% four-quarter average. Next scheduled report: 2026-11-12.

What argues against it

  • Concentration risk — Pipeline: JADE101
  • DATA_ISSUE: analyst_target_implausible (raw $50.12 vs price $16.65 — ratio 3.0×). Rejected, falling back to technical TP.
  • Quality below floor (2.5 < 4.0)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$16.65
Price target
$23.84
Stop
$15.68
Upside to target
+43.2%

Risk check: RSI 18 — a level conventionally read as oversold; trading volume is running 2.1× its average — elevated turnover around the report window.

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare context

JBIO at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$1.11B
P/E (fwd)
-6.5
52-week range
$6.93$28.00
Off 52-week high
40.5%
RSI (14)
18
Volume vs avg
2.08×
Score today
4.9/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks JBIO Earnings Q2 2026 earnings